Hillsborough, NC, United States of America

S Wayne Mascarella

USPTO Granted Patents = 13 (Patent Applications = 1)

CIPO Patents = 4

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 203(Granted Patents)

Location History:

Hillsborough, NC (US) (2003 - 2017)
Research Triangle Park, NC (US) (2022)

Company Filing History:

13 out of 350

Research Triangle Institute

Virginia Commonwealth University

patents

where one patent can have more than one assignee

Years Active: 2003-2022

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11292783 - Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists (2022-04-05),

2. 9750738 - Arylpiperazine opioid receptor antagonists (2017-09-05),

3. 9527823 - Hydroxybupropion analogues for treating drug dependence (2016-12-27),

4. 9512105 - 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists (2016-12-06),

5. 9273027 - Arylpiperazine opioid receptor antagonists (2016-03-01),

6. 8906908 - Hydroxybupropion analogues for treating drug dependence (2014-12-09),

7. 7476679 - Octahydroisoquinoline compounds as opioid receptor modulators (2009-01-13),

8. 6974824 - Kappa opioid receptor ligands (2005-12-13),

9. 6900228 - Opiate compounds, methods of making and methods of use (2005-05-31),

10. 6593348 - Opiate compounds, methods of making and methods of use (2003-07-15),

11. 6559159 - Kappa opioid receptor ligands (2003-05-06),

12. 6552032 - Opiate compounds, methods of making and methods of use (2003-04-22),

13. 6531481 - Opiate compounds, methods of making and methods of use (2003-03-11),

Title: S Wayne Mascarella: Innovator in Opioid Receptor Antagonists

Introduction

S Wayne Mascarella is a notable inventor based in Hillsborough, NC (US), recognized for his significant contributions to the field of pharmacology. He holds a total of 13 patents, showcasing his innovative approach to developing compounds that target opioid receptors.

Latest Patents

Among his latest patents, Mascarella has developed substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists. These potent opioid receptor antagonists are designed for use as pharmacotherapies for treating various conditions, including depression, anxiety, schizophrenia, eating disorders, and addiction to substances such as cocaine, methamphetamine, nicotine, alcohol, and opiates. Additionally, he has worked on arylpiperazine opioid receptor antagonists, which are represented by a specific formula and are aimed at providing effective treatment options for opioid-related disorders.

Career Highlights

Throughout his career, Mascarella has been associated with reputable organizations, including the Research Triangle Institute and Dignity Health. His work has significantly impacted the development of therapeutic agents that address critical health issues.

Collaborations

Mascarella has collaborated with notable individuals in his field, including James Barnwell Thomas and Frank Ivy Carroll. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

S Wayne Mascarella's work in developing opioid receptor antagonists highlights his commitment to addressing pressing health challenges through innovative solutions. His contributions continue to influence the field of pharmacology and improve treatment options for various disorders.

This text is generated by artificial intelligence and may not be accurate.